🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/05/2011 9,96 10,38 9,90 10,08 +0,60% 4,82% 184.533
04/05/2011 10,38 10,44 10,02 10,02 -2,91% 4,05% 183.933
03/05/2011 10,80 10,86 10,32 10,32 -4,97% 5,00% 250.000
02/05/2011 10,86 11,10 10,44 10,86 +1,12% 6,08% 349.550
29/04/2011 11,10 11,28 10,62 10,74 -2,19% 5,95% 913.300
28/04/2011 10,32 10,98 10,20 10,98 +5,78% 7,56% 750.000
27/04/2011 10,50 10,50 10,14 10,38 +0,00% 3,43% 294.817
26/04/2011 10,38 10,50 10,14 10,38 +0,58% 3,47% 233.333
25/04/2011 10,32 10,50 10,14 10,32 +0,58% 3,49% 200.700
21/04/2011 10,62 10,62 10,20 10,26 -2,84% 3,95% 159.750
20/04/2011 10,20 10,62 10,14 10,56 +4,14% 4,71% 285.983
19/04/2011 10,32 10,44 10,08 10,14 -1,17% 3,49% 205.617
18/04/2011 10,38 10,38 10,02 10,26 -0,58% 3,47% 270.567
15/04/2011 10,02 10,38 9,96 10,32 +3,61% 4,19% 202.017
14/04/2011 10,32 10,32 9,96 9,96 -3,49% 3,49% 223.067
13/04/2011 10,38 10,56 10,20 10,32 +1,78% 3,47% 410.217
12/04/2011 9,96 10,38 9,96 10,14 +4,97% 4,22% 534.167
11/04/2011 9,72 9,96 9,54 9,66 -0,62% 4,32% 190.050
08/04/2011 9,84 9,84 9,60 9,72 -1,22% 2,44% 197.383
07/04/2011 9,66 10,02 9,54 9,84 +3,80% 4,97% 518.350
06/04/2011 9,54 9,60 9,36 9,48 +0,64% 2,52% 198.167
05/04/2011 9,42 9,66 9,30 9,42 +0,00% 3,82% 193.117
04/04/2011 9,42 9,66 9,30 9,42 +1,29% 3,82% 380.683
01/04/2011 9,36 9,90 9,12 9,30 -16,67% 8,33% 2.210.917
31/03/2011 11,46 11,52 11,04 11,16 -3,13% 4,19% 154.250
30/03/2011 11,22 11,64 11,22 11,52 +3,23% 3,74% 93.717
29/03/2011 10,68 11,16 10,68 11,16 +3,91% 4,49% 130.250
28/03/2011 10,92 10,98 10,62 10,74 -1,10% 3,30% 114.517
25/03/2011 11,04 11,16 10,74 10,86 -0,55% 3,80% 160.283
24/03/2011 10,98 11,16 10,68 10,92 -0,55% 4,37% 96.100